September 2026 Research Update

This month added clearer examples of AIHA that do not fit the usual "warm IgG" pattern. Across studies, IgA-positive AIHA stood out as a group with frequent relapses over time, while cold-related hemolysis (including paroxysmal cold hemoglobinuria and probable cold agglutinin disease) showed that severe episodes can happen quickly and may be managed very differently depending on the situation. Together, these reports underline that the antibody type (IgA, IgM, complement) can shape both the lab results and the day-to-day course. [1] [2] [3] [4]

In a small center experience plus a published-case review, IgA-positive AIHA often involved more than one antibody type at the same time (for example IgA with IgG), and relapse during follow-up was common. Most people received corticosteroids, and a smaller portion received treatments such as rituximab or IVIG, with infections and blood clots reported in a minority of patients. The main message is that IgA-positive AIHA exists as a recognizable pattern and may not be a one-time event for many people. [1]

Several case reports showed how testing can be challenging in these less typical forms. One teenager had hemolysis after hepatitis A with repeated negative DAT (a common antibody test), and the authors raised the possibility of IgA-driven disease even though IgA on red cells could not be directly proven. This matters because a negative DAT does not always rule out AIHA when symptoms and other lab signs point strongly to hemolysis. [4]

Cold-triggered hemolysis was illustrated at both ends of age. A toddler with postviral paroxysmal cold hemoglobinuria had very severe anemia and kidney injury but recovered with supportive care without complement-blocking treatment, leading the authors to argue that organ problems may be a more meaningful warning sign than anemia severity alone in deciding whether to escalate. A separate report of a frail older adult described probable cold agglutinin disease, where supportive steps like transfusion support and careful cold avoidance were linked with stabilization, although formal cold agglutinin testing was incomplete. [2] [3]

For patients and caregivers, these studies mainly add understanding rather than changing care right now. They help clarify that AIHA can be driven by different antibody types, and that standard tests like the DAT can be negative or show unusual patterns, especially when IgA or cold-related mechanisms are involved. What remains uncertain is how best to predict relapse and which second-line options work best for IgA-positive AIHA, because most data were retrospective or from case reports. For now, the practical value is recognizing that "AIHA" is not one single pattern, and that test results and symptoms may need to be interpreted in the full clinical context. [1] [4] [2] [3]

This month, most human reports described AIHA appearing alongside another major illness rather than as an isolated condition. Across these cases, controlling the underlying trigger (such as a virus, tuberculosis, lupus inflammation, or post-transplant immune changes) was described alongside treatments aimed at hemolysis, and complications like blood clots or organ strain sometimes shaped the immediate risks. The combined picture is that when AIHA happens in a complex medical setting, the "cause around it" may strongly influence testing, treatment choices, and monitoring priorities. [5] [6] [7] [8]

Two infection-linked reports showed different pathways to improvement. In an immunocompetent adult with acute CMV hepatitis, specialized blood bank testing supported mixed AIHA (warm and cold components), and hemolysis was brought under control using a combination that included antiviral therapy, steroids, IVIG, plasma exchange, and transfusions, even though the DAT stayed strongly positive. In a child with an infected cyst felt to be tuberculosis-related, AIHA resolved after surgery and tuberculosis treatment without immunosuppressive therapy, suggesting the immune attack may have calmed once the infection focus was removed. [5] [6]

A lupus-related case highlighted AIHA occurring during a severe abdominal lupus complication (lupus mesenteric vasculitis). After induction with pulse steroids and IVIG, the patient remained clinically stable during follow-up while receiving telitacicept (a B-cell targeted immune therapy) as part of maintenance treatment alongside other lupus medicines, with hemoglobin and complement levels reported to normalize. Because this is a single case with multiple overlapping treatments, it mainly provides an early signal rather than a clear answer about telitacicept's specific role in AIHA. [7]

A pediatric liver transplant case emphasized that complications beyond anemia may appear quickly. The infant developed AIHA after transplant and also had portal vein thrombosis, and the report described improvement after a package of changes including tacrolimus dose reduction, high-dose steroids, rituximab, and therapeutic anticoagulation, with Doppler-confirmed vein reopening. The authors stressed coagulation testing and Doppler monitoring at the time AIHA begins in this transplant setting, pointing to clot risk as part of the clinical picture in at least some patients. [8]

For patients, these reports mainly matter when AIHA happens together with another condition like a recent infection, lupus flare, or transplant-related immune changes. They help clarify that the plan and the risks may depend as much on the underlying illness and complications (like clots) as on the anemia itself, and that lab tests can remain abnormal even when symptoms improve. What remains uncertain is how often these patterns occur and which parts of the multi-step treatments were most important, because the evidence here is almost entirely single-patient reports. The value this month is a clearer picture of the kinds of real-world situations in which AIHA can appear, and what clinicians may look for in those settings. [5] [6] [7] [8]

Beyond individual triggers, this month also added perspective on how AIHA behaves over time in broader groups and complex immune disorders. A large pediatric chart review suggested that children with AIHA or Evans syndrome often present younger and with higher lymphocyte counts than other chronic immune cytopenias, while several reports emphasized that relapse, clot risk, and treatment resistance can become the main challenges. The overall message is that AIHA can be part of a longer immune pattern, and outcomes may depend on the surrounding immune diagnosis as much as on the initial response. [9] [10] [11]

In 180 children with chronic immune cytopenias, AIHA made up about one-third of cases and Evans syndrome about one-tenth. AIHA and Evans syndrome were reported to start at younger ages and to have higher lymphocyte counts, while immunoglobulin levels and T-cell subsets did not differ across groups in this dataset. The study also noted that chronic immune thrombocytopenia had the worst end-of-study treatment response, which helps frame how different immune cytopenias can follow different paths over time. [9]

Two Evans syndrome case reports focused on difficult tradeoffs and complications. One patient with Evans syndrome and multiple sclerosis improved with IVIG and high-dose steroids but did not respond to rituximab, illustrating that responses can vary even to commonly used therapies. Another patient with Evans syndrome had repeated blood clots alongside persistent lupus anticoagulant, and the report described how raising the platelet count with immunotherapy was important to make therapeutic anticoagulation possible without bleeding in that individual. [10] [11]

A commentary discussed whole blood exchange-lymphoplasmapheresis combined transfusion (WLCT) reported in a ceftriaxone-induced immune hemolytic anemia case, presenting it as a plausible rescue approach but not proven to work better than other options. The authors highlighted unanswered questions about safety, reproducibility, and the need for standardized protocols and multicenter data. This adds context for patients who may read about dramatic procedures online, showing how early such evidence can be. [12]

For patients and caregivers, this set of studies mainly helps set expectations and language for follow-up discussions, rather than pointing to a new standard treatment. The pediatric cohort helps clarify that AIHA and Evans syndrome may show up early in childhood and can have immune system patterns (like higher lymphocyte counts) that differ from other long-lasting low-blood-count disorders. The Evans syndrome cases underline that complications such as clotting can be part of the picture for some people, and that responses to therapies like rituximab can be unpredictable in individuals. What remains uncertain is how to best predict who will relapse or develop clots, because much of this month's detail came from single-patient experiences and retrospective data. [9] [10] [11] [12]

Two studies this month were relevant mainly as background rather than direct evidence for human AIHA treatment choices. A veterinary IMHA study in cats described outcomes with prednisolone with or without cyclosporin, and a human hospital cohort described safety and outcomes of therapeutic plasma exchange across many conditions. Together, they offer context about relapse and procedure side effects, but they cannot be read as proof of benefit for any specific AIHA approach in people. [13] [14]

In 37 cats with immune-mediated hemolytic anemia, outcomes were described for prednisolone alone versus prednisolone plus cyclosporin, but the authors emphasized that treatment selection was not randomized and cats given cyclosporin tended to be sicker at the start. Relapses were reported mainly while cats were still on therapy, and long-lasting remission off treatment was rare. Adverse effects such as increased appetite, lethargy, and reduced appetite were common in both groups, showing the practical burden of long-term immune suppression in this animal model. [13]

In a 7-year cohort of 221 adults receiving therapeutic plasma exchange for many different disorders, most patients were reported to have a clinical response, and side effects were common but limited to mild-to-moderate severity in this center's experience. AIHA was reported among the conditions with the highest response rates (above 85%) and no deaths, but it was part of a small group of 13 patients with blood-related conditions among 221 with very diverse diagnoses, so the main contribution here is procedural context: what kinds of short-term issues can occur around plasma exchange in routine hospital care. Because the study looked back at records, had no comparison group, and included few people with AIHA, it cannot show how well plasma exchange works for AIHA compared with other treatments. [14]

For patients, this section is mostly about perspective. The cat study can help people understand that immune-mediated hemolysis often needs prolonged immune suppression and that side effects and relapse can be practical challenges, but animal results do not reliably predict human outcomes. The plasma exchange cohort adds a safety snapshot of the procedure in a real hospital setting across diseases, which may be useful background if someone hears about plasma exchange as part of severe hemolysis care. What remains uncertain from these studies is whether any of these approaches improve outcomes specifically for people with AIHA, because neither study was designed to answer that question in humans with AIHA. [13] [14]